Docket No.: 20855/0205125-US0 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Akio Nakamura

Application No.: National Phase of

Confirmation No.: N/A

PCT/JP2005/001492

Art Unit: N/A

Filed: Concurrently Herewith

Examiner: Not Yet Assigned

For: GLYCOSIDE PRODRUG OF 5-AMINOSALICYLIC ACID

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

A summary/abstract translation of the non-English language documents is enclosed.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and nonpatent literature in accordance with 37 CFR 1.98(a)(2).

Figure M. Pregioon Rog. Res 63,670

Other information being provided for the examiner's consideration follows:

An International Search Report, mailed April 19, 2005, which issued during the prosecution of International Application No. PCT/JP2005/001492 which corresponds to the present application.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "brior att" for this invention unless socifically designated as such

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: August 3, 2006

Respectfully submitted,

4

jama Goldenson

Registration No.: 52,949 DARBY & DARBY P.C.

P.O. Box 5257 New York, New York 10150-5257 (212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

Substitute for form 1449A88PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT					to respond to a collection of information unless it contains a valid OMB control numb Complete If Known				
					Application Number Not Yet As		signed		
					Fling Date First Named Inventor		Concurrently Herewith Akio Nakamura		_
					ArtUnit		N/A		
(Use as meny sheets as necessary)					Examiner Name		Not Yet Assigned		
est		1 of 2			Altomey Docket Number		20855/0205125-US0		
		100	U.S.	PATENT	T DO	CUMENTS			-
aminer	Cite	Document Number	Publication D				v .	Pages, Columns, Lines, Who Relevant Passages or Releva	
ap.	No.1	Number Kind Code ² (#known	MM-00-YYY	Ÿ	Applicant of Clied Document		ment	Figures Appear	
_	AA*	US-4,837,229	06-06-198	9 Roke	is et	al.			
			FOREIG	N PATE	NT	DOCUMENTS			
kaminer kisik*	Cite	Foreign Patent Document Country Code ² -Number ² -Kind Code ² (Mirrown)		MACCOTTTT		Name of Po		Pages, Columns, Lines, Where Relevant Passage	.1
	No.1					Applicant of Ct		or Relevent Figures Appear	:
	BA	WO-84/04041-A1		10-25-19	984	THE REGENTS UNIVERSITY O CALIFORNIA			Ţ
	88	JP-60-501105-A		07-18-19	985	THE REGENTS UNIVERSITY O CALIFORNIA		Corresponds to Citation No. BA	
	ВС	JP-60-69061-A							
AMINE science to Cris	R: Initial Include No. are			is in conto		HENNING BER CHEMIE- UND PHARMAWER! with MPEP 609, Dra NO: Those application was find after Ju-	(Corresponds to Citation No. AA letter from the conformance of which with an single extens, a waitable in the FW. 1 App. 2 2010 M. 2 For Office that	
AMINE science na Cris puz cito stocum scient st sible.	R: Initial Include No. are fron desa ent, by the electric in Applicant	If reference considered, wheth copy of this form with next co not supplied (under 37 CPR 1 gration number (options). " Se to beverlate root (WPPO Stan umber of the patient document. It is option it check mark here.	er or not citation emunication to a .55(a)(2)(0)() bec- ne Kinds Codes dard ST.3). Fr. ³ Kind of docum if English langue	is in conto oppicant. suse that a of USPTO or Japanes ent by the ge Translet	mano CITE applica Palent applica applica ion is	CHEMIE- UND PHARMAWER! e with MPEP 606. Drz NO.: Those application size was find after Jul I Documents of arror Jul ent documents, this indi- priste symbols as indicationed.	(in the through of (a) which are m is 30, 2003 or is solo, goy or MPSI icalion of the yes siled on the docu	Citation No. AA	nd in cer issu r m
		If reference considered, wheth copy of this form with next on not supplied (under 37 CFR 1 paston number (options). "3 to be dealer code (WFO Stan umber of the painted document it is to piace a check mark bern."	or or not citation immunication to a 58(a)(20)(ii) be on Kinds Codes dard ST.3). Fr What or docum if English langue ION PATEN	is in conto applicant. Suse that a suse that a suse that a suse that a suse that are that the pe Translate	CITE application is position is	CHEMIE- UND PHARMAWER! e with MPEP 400. Dre NO.: Those application was fire after Ju! I Documents at annua. In the comments of annual to the comments at annual to the comments of the comments. JRE DOCUMEN	we like through of (iii) which are m is 30, 2003 or is solicated or MPR isalion of the yea sided on the docu	Citation No. AA lelion if not in conformance of the dwish an single attention available in the FW. App 901.04. ² Port Office that or of the mign of the Emperment under WIPO Standard E	
AMINE selered na Cita pue cita docum sede it sible. ¹	Cite No.1	If reference considered, whether copy of the form with east on cot supplied present 27 CFR 1 system number (spicore). "System number (spicore)." If the herbitalist code (NPPO Stanumber of the patient document is to place a check mark been include names of the aud magazine, journal, se	or not clation strong to the s	is in confor ppicent. " suse that a of USP10 or Japones ent by the ge Translet T LITES LLETTE and/or a	Palente police p	CHEMIE- UND PHARMAWER! e with although 606, Drs. No. Those application also files after July floorments at general and documents, the indicentation was strong and documents, the indicentation of the strong of	whethrough of (s) which are m as 30, 2003 or is solication of the yealed on the document of the properties of the proper	Citation No. AA leikins finct in conformance stand with an indige attention available in the FIV. 1 App 2010. 2 Error Office that or of the reign of the Emperoment under WIPO Standard S. a), Sile of the item (book, wher(s), publisher, city)	nd r licer lessu r m T.11
miņe	Cte No. ¹ CA	If reference considered, wheth copy of the form with next on caspaign (used 27 CFR 11 person number (spicorat). "As well as the order of the constant of the c	or or not catalon remunication to a 18(0)(2)(0)() becee tonds Codes aged ST.3). "F. "Keet of docume if english language ION PATEN histor, symposium fish, symposium disease, on 4, pp. 447-4	is in conformation in a conformation in the co	mano CITE applica Palent le peli leon s RATI RS), p. elc. 20uni isalia CXy	CHEMIE- UND PHARMAWER IN 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10	w line through of 100) which are may 30, 2003 or is appropriate called on the document. The appropriate arms—see appropriate arms—see nur or the treatment LTB4 for	Citation No. AA leiton finct in conformance or mad with an single estantial, socialists in the FW. 1 App POLIA. Since Office that ment under WIPO Standard S to the first of the litem (book, shorifs), publisher, city and of idiopathic mation, Folia	nd it
miņe	Cte Ne. ¹ CA	If reference consistent, which carry of the term with east on not suppose (unear 37 CPH) and to rect on the suppose (unear 37 CPH) are to relate code (MPO Stame 18 to piles a check mark have a check mark have a check mark have magazine, journal, as KOICHI NAKAMARI (inflammatory bowell Pharmacol, Jun, 10 KOICHI NAKAMARI, Jun, 10 KOICHI NAKAMARI (L) KOICHI NAKAMARI (L) KOICHI NAKAMARI (L) KOICHI NAKAMARI (L) Jun, 10 KOICHI NAKAMARI (L) KOICHI NAKAMARI (L) Jun, 10 KOICHI NAKAMARI (L) KOICHI (L) KOICHI NAKAMARI (L) Jun, 10 KOICHI (L) KOICHI	er or not clation minuscribin to a \$10(a)(20)(ii) bec found for the control of finglet language HOME CAPITI of CAPIT	is in conforpition. Japanes and USP10 or Japanes well by the per Translet T LITES LETTE m, catalog and/or oct of me reactive 57, 1994 oct of me 511, 199	mencicone popular Palente le pell le p	CHEMIE- UND PHARMAVERY of the PHARMAVERY OF SOLUTION OF THE SO	whee through of (s) which are my so, 2000 or is principle or MPR called of the year shed on the document of the year shed on the document of the year shed on the document of the treatment of th	citation No. AA lettor Fact in conformance index with an index electric socialists in the FFW. 1/20, 9910.10. Street Office that or of the reign of the Empera- socialists of the Street index VIPO Standard of t	nd it is in
miņe	Cte No. ¹ CA	If reference consistence, whether company of the form with next can not supplied punder 37 CPH a representation	er or not clains memascrism to a 510/2(30) be en Kndz Code; en Kndz Code; en Kndz Code; "Knd of document if finglish language ION PATEN hour (in CAPITITIII), et al., Effection, pp. 447-4, et al., Effection, pp. 447-4, pp. 303-2, Dissossition, pp. 503-2, Dissossition, pp. 503-2, pp. 303-2, Dissossition, et al., Effection, et al., et al., Effection, et al., et	is in conto pplicate. " suse that or USP10 or Japonese and by the pa Translate T LITES V. LETTE m, catalog and/or or oct of me reactive 57, 1994 ct of me fill 1, 199 of 5-An	RS), etc. counts resolution is counts	CHEMIE- UND PHARMAWER : UND PHARMAWER : UND PHARMAWER : UND PHARMAWER : UND EXPENDED : UND EXPEN	when through of the control of the c	Citation No. AA letter if not in conformance is available in the BW. App. available in the Bw. available in t	
miņe	Cte Ne. ¹ CA	If ofference contributed, wheth copy of the form with host can not supplied growth of Cofference and Cofference	w or not delition to a 1300/2009 to the	is in conto pplicate. " suse that or USP10 or Japonese and by the pa Translet T LITES U. LETTE M. Catalog and/or cot of me cot of me fill, 199 of 5-Annal of Go	Palent politica polit	CHEMIE- UND PHARMAVERY PHARMAVERY PHARMAVERY NO. Those approach no. Those approach not documents, the not proach as indo notes approach not documents, the not notes approach notes a	when through or to the through or to the through or to the through or t	Citation No. AA alkbox feet. in conformace, which is the region extent avoidable in the FW. 14,00 20 20 10.4. "Size of long is extrain avoidable in the FW. 14,00 20 10.4. "Size of long in the feet of the region of he feet of the region of he feet of the region of he feet of the	nd it is in
miņe	CA CB	Inflatoric consistent, when you can see the control of the form with next can complete number (organized number (organiz	er or not citation error not citation error not citation error not citation error not codes error code	is in control policient. " suse that is of userto or Japones ent by the is of userto or Japones ent by the is of the control policient of the control policient ent of me reactive 57, 1994 ct of me into 111, 199 of 5-Annal of Grand of Gra	Palent in the pa	CHEMIE- UND PHARMAWER	w the through of only which has no only which has no only only only only only only only o	Citation No. AA altered fine in contemporary and with an indige electricity, and with an indige electricity, and with an indige electricity, and with a single electricity, and of indige e	T.11
miņe	CA CB CC	Inference consistent, when copy of the form with head on copy of the form of the header code (Post Parameter of the patient december	er or not claino situación lo lo situación lo lo situación lo situació	is in control popularies. " suse that is of userto for mandror anditor oct of mandror oct of mandror for userto for mandror for formal of SA nad of SA fic drug of SA fic drug of sa peuticia appeutica appeutica appeutica appeutica appeutica suser popularies for user	RATI RESIDENT RESIDEN	CHEMIE - UND PHARMANWERS with safety 600, Or 00. These special of the control of	w line through of opposite the many of the control of the many of the control of	Citation No. AA altered fine in conformance, and with an indirect with a i	nd it is in
miņe	CA CA CB CC CD	Inflamor considered, when we have considered and co	or or not calation in the second of the seco	is in control popularia. some that is or userfor or Japanes ent by the per Translat T. LETTE m., catalog and/or c ct of me 111, 1999 of 5-An nale of Ge fine drug o Studies o apputics scalicities Antilusee	RATI RS), etc. count issalia innocastro astro astro astro astro astro astro astro astro astro ar Effi	CHEMIE - UND PHARIAMVERS with here to the Common - Commo	(w in through of the company of the	Citation No. AA citation No. The Citation No. AA citati	nd r
miņe	Cta No. ⁵ CA CB CC CD CE	Inflantoc consistent, which was a consistent of the first open of the form with read on grates number (persons). The read of the first open open open open open open open open	w or not deline. 3504/2009 becen so find to the street of	is in coolbing to coolbing the coolbing to the	Palente patente patent	CHEMIE UND PHARMANUPS as with with Fig. 2. The separation of the s	we fee through on the second of the second	Citation No. AA citation No. The continued of the continued of the continued of the citation	nd r

Examiner Signature